Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Replacement: Total Voting Rights

24 Apr 2024 07:00

RNS Number : 7691L
IDOX PLC
24 April 2024
 

24 April 2024

Idox plc

("Idox" or "Group" or "Company")

Correction - Exercise of Share Options and Total Voting Rights

The following amendment has been made to the "Exercise of Share Options & Total Voting Rights" announcement released 17 April 2024 at 12.43pm under RNS No. 0060L

The original announcement incorrectly stated that the figure to be used for both the total number of ordinary shares in issue following Admission and the total number of ordinary shares with voting rights in the Company was 457,771,879. The correct figure to be used for the total number of ordinary shares in issue following Admission will be 459,377,981. The correct figure to be used for the total number of ordinary shares with voting rights in the Company will be 459,377,981.

All other details remain unchanged. The full amended text is shown below.

Idox plc (AIM: IDOX) a leading supplier of specialist information management software and geospatial data solutions to the public and asset-intensive sectors, announces that it has issued 77,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") pursuant to an exercise of options by employees under its Idox plc Long Term Incentive Plans.

An application has been made for the 77,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. on or around 22 April 2024.

The Company holds no ordinary shares in treasury. The total number of ordinary shares in issue following Admission will be 459,377,981. Therefore, the total number of ordinary shares with voting rights in the Company will be 459,377,981.

The above figure of 459,377,981 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

Idox plc

+44 (0) 870 333 7101

Chris Stone, Non-Executive Chairman

investorrelations@idoxgroup.com

David Meaden, Chief Executive

 

Anoop Kang, Chief Financial Officer

 

 

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

Paul Gillam

 

Adam Telling

 

 

MHP

+ 44 (0) 20 3128 8100

Reg Hoare

 idox@mhpgroup.com

Ollie Hoare

Matthew Taylor

 

About Idox plc

For more information see www.idoxplc.com @Idoxgroup

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRIJMPTMTITBRI
Date   Source Headline
24th Apr 20184:32 pmRNSHolding(s) in Company
24th Apr 201810:24 amRNSHolding(s) in Company
23rd Apr 20183:40 pmRNSHolding(s) in Company
19th Apr 20183:58 pmRNSResult of AGM and Board Change
19th Apr 20183:54 pmRNSAGM Statement and Trading Update
19th Apr 20187:00 amRNSAGM Statement and Trading Update
27th Mar 20185:17 pmRNSDirector/PDMR Shareholding
27th Mar 201811:02 amRNSPosting of Annual Report and Notice of AGM
22nd Mar 20185:27 pmRNSHolding(s) in Company
19th Mar 201811:22 amRNSHolding(s) in Company
15th Mar 20185:17 pmRNSVesting of LTIP
8th Mar 20184:43 pmRNSHolding(s) in Company
1st Mar 201812:25 pmRNSDirectorate Change
1st Mar 201811:30 amRNSHolding(s) in Company
1st Mar 20187:00 amRNSFinal Results
20th Feb 201812:24 pmRNSHolding(s) in Company
2nd Feb 20184:12 pmRNSHolding(s) in Company
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 20184:52 pmRNSHolding(s) in Company
25th Jan 201812:34 pmRNSDirector/PDMR Shareholding
5th Jan 20184:40 pmRNSSecond Price Monitoring Extn
5th Jan 20184:35 pmRNSPrice Monitoring Extension
3rd Jan 201810:51 amRNSHolding(s) in Company
27th Dec 20171:48 pmRNSHolding(s) in Company
13th Dec 20177:00 amRNSYear End Update and Board Change
14th Nov 20173:45 pmRNSYear End Trading Update
2nd Nov 20171:31 pmRNSDirector Update
22nd Sep 20172:33 pmRNSExercise of Options and Total Voting Rights
20th Sep 20179:32 amRNSHolding(s) in Company
4th Sep 201710:38 amRNSDirectors' Dealing, Exercise of Options & TVR
1st Sep 20176:16 pmRNSHolding(s) in Company
23rd Aug 20176:06 pmRNSHolding(s) in Company
17th Aug 20177:00 amRNSAcquisition
4th Aug 20174:20 pmRNSDirector and PCA Dealing
14th Jul 20173:52 pmRNSDirector/PDMR Shareholding
6th Jul 20174:35 pmRNSPrice Monitoring Extension
29th Jun 20175:23 pmRNSDirector/PDMR Shareholding and Total Voting Rights
6th Jun 20177:00 amRNSHalf-year Report
18th May 20177:00 amRNSHalf Year Trading Update and Notice of Results
17th May 20174:31 pmRNSHolding(s) in Company
18th Apr 20173:45 pmRNSDirector/PDMR Shareholding and Total Voting Rights
7th Apr 20172:27 pmRNSDirector/PDMR Shareholding
22nd Mar 20179:22 amRNSDirector and PCA Dealing
24th Feb 201712:53 pmRNSResult of AGM
24th Feb 20177:00 amRNSAGM Trading Update
15th Feb 20172:55 pmRNSHolding(s) in Company
14th Feb 20171:24 pmRNSExercise of Options and Total Voting Rights
10th Feb 20173:39 pmRNSDirector/PDMR Shareholding
6th Feb 20176:30 pmRNSDirector/PDMR Shareholding
3rd Feb 20179:48 amRNSDirectors' Dealing, Exercise of Options and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.